Contact | Print version | PDF version | Send article | RSS-Feed

Cytochroma opens U.S. headquarters in Illinois

05 May 2008 - Cytochroma announced the opening of its U.S. headquarters in Bannockburn, Illinois, located in the greater Chicago area. The site will serve as the Company's base for U.S. commercial activities and for the expansion of its North American clinical and regulatory operations.
 
The expansion into the U.S. shall ensure that appropriate resources are available to support the Company's numerous planned clinical programs as well as subsequent U.S. product launches. Members of Cytochroma's current management team to be based in the Bannockburn office include Joel Z. Melnick, M.D., Vice President of Clinical and Regulatory Affairs and Eric J. Messner, MBA, Vice President of Commercial Operations. The Company will retain and continue growing its existing corporate headquarters in Markham.
 
Charles W. Bishop, PhD., President and CEO, commented, "This is an ideal time for Cytochroma to establish U.S. operations, as we move our lead programs into mid- to late-stage clinical trials and execute plans to develop our commercial infrastructure. The Chicago area is a prime location for Cytochroma, given the presence of a number of world-class pharmaceutical and healthcare companies focused on the chronic kidney disease market and the strong intellectual capital present in the region."
 
Cytochroma has a diverse portfolio of Vitamin D-based therapeutics designed to treat disorders related to abnormal or insufficient Vitamin D metabolism in chronic kidney disease (CKD) patients.